Utilization of 3D bioprinting technology in creating human tissue and organoid models for preclinical drug research - State-of-the-art

Int J Pharm. 2023 Sep 25:644:123313. doi: 10.1016/j.ijpharm.2023.123313. Epub 2023 Aug 12.

Abstract

Rapid development of tissue engineering in recent years has increased the importance of three-dimensional (3D) bioprinting technology as novel strategy for fabrication functional 3D tissue and organoid models for pharmaceutical research. 3D bioprinting technology gives hope for eliminating many problems associated with traditional cell culture methods during drug screening. However, there is a still long way to wider clinical application of this technology due to the numerous difficulties associated with development of bioinks, advanced printers and in-depth understanding of human tissue architecture. In this review, the work associated with relatively well-known extrusion-based bioprinting (EBB), jetting-based bioprinting (JBB), and vat photopolymerization bioprinting (VPB) is presented and discussed with the latest advances and limitations in this field. Next we discuss state-of-the-art research of 3D bioprinted in vitro models including liver, kidney, lung, heart, intestines, eye, skin as well as neural and bone tissue that have potential applications in the development of new drugs.

Keywords: 3D printing; Drug screening; Organoid models; Pharmaceutical application; Tissue models.

Publication types

  • Review

MeSH terms

  • Bioprinting* / methods
  • Humans
  • Organoids
  • Pharmaceutical Research*
  • Printing, Three-Dimensional
  • Technology
  • Tissue Engineering / methods
  • Tissue Scaffolds